- ISIN
- IL0011313900
- CUSIP
- 001131390
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Mar 13, 2014
Highlights
- Market Cap
- $4.55M
- Enterprise Value
- $563.40K
- EPS (TTM)
- -$1.93
- EBITDA (TTM)
- -$8.49M
- Year Range
- $0.41 - $2.34
- ROA (TTM)
- -55.34%
- ROE (TTM)
- -65.32%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
GLMD Performance Chart
Galmed Pharmaceuticals Ltd. (GLMD) is down 7.9% since the beginning of the year. At $1 per share, GLMD is trading 70.5% below its 52-week high of $2. Investors who bought $1,000 worth of GLMD shares 5 years ago would now be looking at an investment worth $1.
Loading charts...
Returns By Period
Galmed Pharmaceuticals Ltd. (GLMD) has returned -7.91% so far this year and -52.34% over the past 12 months. Over the last ten years, GLMD has returned -50.21% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.
Galmed Pharmaceuticals Ltd.
- 1D
- -4.96%
- 1M
- 21.01%
- YTD
- -7.91%
- 6M
- -27.93%
- 1Y
- -52.34%
- 3Y*
- -77.01%
- 5Y*
- -73.13%
- 10Y*
- -50.21%
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.25%
- YTD
- 11.16%
- 6M
- 11.43%
- 1Y
- 28.20%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
GLMD Monthly Returns History
Based on dividend-adjusted daily data since Mar 13, 2014, GLMD's average daily return is -0.04%, while the average monthly return is -2.49%.
Historically, 41% of months were positive and 59% were negative. The best month was Sep 2024 with a return of +103.0%, while the worst month was May 2022 at -69.2%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 10 months.
On a daily basis, GLMD closed higher 44% of trading days. The best single day was Sep 17, 2024 with a return of +290.2%, while the worst single day was Sep 18, 2024 at -54.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -5.40% | -13.87% | -19.87% | 16.33% | 32.21% | -8.29% | -7.91% | ||||||
| 2025 | -12.85% | -23.02% | -32.71% | -9.72% | 10.00% | 28.67% | -11.41% | -22.09% | 8.66% | -0.72% | -31.39% | -20.15% | -76.47% |
| 2024 | -17.60% | 5.74% | -12.64% | 1.65% | 5.14% | -25.70% | 11.78% | -8.37% | 102.96% | -51.31% | -14.37% | 11.54% | -41.58% |
| 2023 | 32.22% | -27.39% | -11.15% | -27.32% | -0.86% | -35.14% | -61.54% | -29.57% | -23.46% | -38.71% | -6.58% | 28.17% | -93.93% |
| 2022 | -10.99% | -11.11% | 10.42% | 4.40% | -69.18% | 27.05% | -22.75% | -7.57% | -32.97% | 22.19% | -23.20% | 71.29% | -72.53% |
| 2021 | 18.97% | 7.30% | -13.60% | -4.96% | -20.25% | 16.92% | -18.09% | 31.33% | -14.68% | -11.47% | 2.02% | -27.78% | -41.48% |
Benchmark Metrics
Galmed Pharmaceuticals Ltd. has an annualized alpha of -20.46%, beta of 1.00, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since March 14, 2014.
- This stock participated in 233.06% of S&P 500 Index downside but only -27.52% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -20.46%
- Beta
- 1.00
- R²
- 0.02
- Upside Capture
- -27.52%
- Downside Capture
- 233.06%
Return for Risk
Risk / Return Rank
GLMD ranks 17 for risk / return — in the bottom 17% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Galmed Pharmaceuticals Ltd. (GLMD) and compare them to S&P 500 Index.
| GLMD | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.61 | 2.39 | -3.00 |
Sortino ratioReturn per unit of downside risk | -0.63 | 3.25 | -3.88 |
Omega ratioGain probability vs. loss probability | 0.93 | 1.43 | -0.50 |
Calmar ratioReturn relative to maximum drawdown | -0.66 | 3.11 | -3.77 |
Martin ratioReturn relative to average drawdown | -0.95 | 14.38 | -15.33 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Galmed Pharmaceuticals Ltd.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Galmed Pharmaceuticals Ltd. was 99.99%, occurring on Mar 30, 2026. The portfolio has not yet recovered.
The current Galmed Pharmaceuticals Ltd. drawdown is 99.98%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -99.99%Mar 2026 | 7y 9mo | — | 7y 11moJun 2018 - now |
2016 bear market2016 | -81.30%Nov 2016 | 2y 7mo | 1y 7mo | 4y 2moMar 2014 - Jun 2018 |
Drawdown Indicators
| GLMD | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.99% | -56.78% | -43.21% |
Max Drawdown (1Y)Largest decline over 1 year | -79.62% | -9.10% | -70.52% |
Max Drawdown (3Y)Largest decline over 3 years | -99.16% | -18.90% | -80.26% |
Max Drawdown (5Y)Largest decline over 5 years | -99.93% | -25.43% | -74.50% |
Max Drawdown (10Y)Largest decline over 10 years | -99.99% | -33.92% | -66.07% |
Current DrawdownCurrent decline from peak | -99.98% | 0.00% | -99.98% |
Average DrawdownAverage peak-to-trough decline | -74.34% | -10.72% | -63.62% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 55.31% | 1.97% | +53.34% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Galmed Pharmaceuticals Ltd. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Galmed Pharmaceuticals Ltd. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for GLMD in comparison with other companies in the Biotechnology industry. Currently, GLMD has a P/B value of 0.3. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with GLMD
Add Galmed Pharmaceuticals Ltd. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with GLMD